1. Inicio
  2. Proyectos y Estudios
  3. A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH CHEMORADIOTHERAPY (CRT) VERSUS CRT ALONE IN PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) (KEY NOTE-992.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH CHEMORADIOTHERAPY (CRT) VERSUS CRT ALONE IN PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) (KEY NOTE-992.

Datos básicos

ENSAYO CLÍNICO MK-3475-992 2019-004023-20 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2020 Año de finalización: 2026

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

MERCK SHARP & DOHME CORP., FILIAL DE MERCK & CO., INC.
MERCK SHARP & DOHME DE ESPAÑA S.A.

Cita

Compartir